These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33423388)

  • 1. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
    Belančić A; Kresović A; Troskot Dijan M
    Clin Obes; 2021 Apr; 11(2):e12439. PubMed ID: 33423388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.
    Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA
    Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.
    Banerjee Y; Pantea Stoian A; Silva-Nunes J; Sonmez A; Rizvi AA; Janez A; Rizzo M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1309-1315. PubMed ID: 34424130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
    Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
    Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
    Abdelmalek MF; Harrison SA; Sanyal AJ
    Diabetes Obes Metab; 2024 Jun; 26(6):2001-2016. PubMed ID: 38511418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
    Lu JM
    Adv Ther; 2019 Apr; 36(4):798-805. PubMed ID: 30859500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges.
    Huang X; Liu J; Peng G; Lu M; Zhou Z; Jiang N; Yan Z
    J Endocrinol; 2024 Sep; 262(3):. PubMed ID: 38916409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
    Patel Chavez C; Cusi K; Kadiyala S
    J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
    Shaefer CF; Kushner P; Aguilar R
    Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
    Triplitt C; Solis-Herrera C
    Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.
    Monda VM; Voci C; Strollo F; Passaro A; Greco S; Monesi M; Bigoni R; Porcellati F; Piani D; Satta E; Gentile S
    Diabetes Ther; 2023 Dec; 14(12):2127-2142. PubMed ID: 37801224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.
    Bendotti G; Montefusco L; Lunati ME; Usuelli V; Pastore I; Lazzaroni E; Assi E; Seelam AJ; El Essawy B; Jang J; Loretelli C; D'Addio F; Berra C; Ben Nasr M; Zuccotti G; Fiorina P
    Pharmacol Res; 2022 Aug; 182():106320. PubMed ID: 35738455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.
    Scheen AJ
    Expert Opin Drug Saf; 2024 Jul; 23(7):797-810. PubMed ID: 38738549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of GLP-1 Analogs in the Management of Diabetes and its Secondary Complication.
    Sivakumar PM; Premkumar B; Prabhawathi V; Prabhakar PK
    Mini Rev Med Chem; 2021; 21(20):3166-3182. PubMed ID: 33888049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity.
    Winther JB; Holst JJ
    Diabetes Obes Metab; 2024 Sep; 26(9):3501-3512. PubMed ID: 38853300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.